GE HealthCare Technologies Reports Q2 2026 Earnings Beat

What happened

GE HealthCare Technologies reported second-quarter 2026 results that surpassed Wall Street expectations. Adjusted earnings per share came in at $1.13, beating the consensus estimate of $1.04. Revenue increased 5.7% year-over-year to $5.3 billion, ahead of the expected $5.26 billion. The company achieved record organic order growth of 11.1%, with strength across all operating segments. The book-to-bill ratio reached 1.15 times, and the order backlog expanded to $23.9 billion. Organic revenue grew 3.5%, driven by the Pharmaceutical Diagnostics and Advanced Imaging Solutions businesses in the United States, Europe, the Middle East, and Africa. However, the Patient Care Solutions division faced continued headwinds, with revenue declining 13.5% year-over-year. Adjusted EBIT margin slipped 40 basis points to 14.2%, reflecting weakness in Patient Care Solutions and higher costs for memory chips, oil, and freight. The company also received $129 million in tariff refunds, which contributed to net income. Cash flow from operating activities increased to $168 million, up $74 million from the prior year, while free cash flow reached $68 million, an increase of $61 million year-over-year. Management reaffirmed full-year 2026 guidance, expecting organic revenue growth of 3.0% to 4.0%, adjusted EBIT margin of 15.4% to 15.7%, adjusted EPS of $4.80 to $5.00, and free cash flow of approximately $1.6 billion.

Why it matters

The strong order growth and expanded backlog are significant for GE HealthCare because they signal improving pricing power and future revenue visibility after a challenging period. Earlier in the year, the company had lowered its full-year earnings guidance due to a $250 million increase in costs from memory chips, oil, freight, and raw materials. With relatively long sales cycles, GE HealthCare struggled to react quickly by raising prices and had to work through a backlog secured before the cost inflation hit. The record 11.1% organic order growth now implies that the company is successfully implementing price increases and overcoming those cost pressures. CEO Peter Arduini highlighted strong commercial execution and the adoption of new products, including those with embedded AI, which are expected to drive further pricing improvements. CFO James Saccaro noted that cost actions are holding and should contribute more meaningfully to margins in the second half of 2026 and into 2027. The $23.9 billion backlog provides greater confidence in the company's ability to convert orders into revenue and improve profitability going forward.

Bigger picture

The medical technology sector has faced headwinds from rising input costs and supply chain challenges, which have pressured margins across the industry. GE HealthCare's ability to grow orders across all segments-Pharmaceutical Diagnostics, Advanced Imaging Solutions, and others-demonstrates resilient demand for healthcare technology even amid cost inflation. The adoption of AI-embedded products reflects broader industry trends toward advanced diagnostics and imaging solutions that improve patient outcomes and operational efficiency. However, the 13.5% revenue decline in Patient Care Solutions highlights ongoing challenges in certain segments, potentially tied to hospital budget constraints or competition. The company's performance in the United States, Europe, the Middle East, and Africa indicates geographic diversification, though specific regional dynamics were not detailed. The $129 million tariff refund also points to ongoing trade policy impacts on multinational healthcare equipment manufacturers. Overall, GE HealthCare's results suggest the company is navigating a complex operating environment while positioning itself for improved profitability through pricing discipline and innovation.

What to watch

Investors should monitor whether GE HealthCare can sustain its order momentum in the second half of 2026, particularly as the company works through its $23.9 billion backlog and converts orders into revenue. Key indicators include whether adjusted EBIT margin improves sequentially toward the full-year target of 15.4% to 15.7%, as management expects cost actions and improved pricing to take effect. Progress in stabilizing or reversing the 13.5% revenue decline in Patient Care Solutions will also be important, as continued weakness could offset gains in other segments. The adoption rate of new AI-embedded products and their contribution to pricing and margins will provide insight into the company's innovation strategy. Additionally, any further changes in input costs for memory chips, oil, or freight could impact profitability, so commentary on supply chain trends will be relevant. Finally, watch for updates on the company's ability to achieve its full-year free cash flow target of approximately $1.6 billion, as cash generation is a critical measure of financial health.